Related Experiment Video

Updated: Feb 6, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.2K

Chronic active hepatitis induced by Pazopanib mimicking hypervascular liver metastases in a patient with recurrent

Ana Ezponda1, Ignacio González De La Huebra1, Marta Calvo1

  • 1Department of Radiology, Clínica Universidad de Navarra, Pamplona 31008, Spain.

Oncology Letters
|August 22, 2018
PubMed

Insights

Pazopanib, a soft tissue sarcoma treatment, can cause chronic active hepatitis. This study details a novel case with liver lesions mimicking metastases, crucial for accurate diagnosis and treatment continuation.

Area of Science:

  • Oncology
  • Hepatology
  • Pharmacology

Background:

  • Pazopanib is a multitargeted tyrosine-kinase inhibitor for advanced non-adipocytic soft tissue sarcoma (STS).
  • Vascular endothelial growth factor receptor inhibition by Pazopanib can cause adverse effects, including hepatotoxicity.
  • Early identification of Pazopanib-induced liver injury is critical for patient management.

Purpose of the Study:

  • To report the first case of Pazopanib-induced chronic active hepatitis in a patient with recurrent STS.
  • To describe novel hypervascular liver lesions observed in this patient, which mimicked metastases on CT scans.
  • To highlight the importance of recognizing these findings to prevent misdiagnosis and premature treatment cessation.

Main Methods:

  • A case study of a patient with recurrent STS treated with Pazopanib.
  • Biopsy-proven diagnosis of chronic active hepatitis.
  • Radiological assessment using computed tomography (CT) to evaluate liver lesions.

Main Results:

  • The patient developed biopsy-proven Pazopanib-induced chronic active hepatitis.
  • CT scans revealed multiple hypervascular liver lesions, previously undescribed, that were indistinguishable from metastases.
  • These lesions represent a novel finding associated with Pazopanib-induced chronic active hepatitis.

Conclusions:

  • Pazopanib can induce chronic active hepatitis with unique radiological findings in STS patients.
  • Hypervascular liver lesions in patients on Pazopanib may represent drug-induced hepatitis, not metastases.
  • Awareness of this association is vital for accurate staging and avoiding unnecessary treatment discontinuation.
Keywords:
Pazopanibchronic active hepatitishypervascular lesionsmetastasessoft tissue sarcomatoxicitytyrosine kinase inhibitors

More Related Videos

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver09:02

Percutaneous Hepatic Perfusion PHP with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Published on: July 31, 2016

12.4K
Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma09:52

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

Published on: January 25, 2015

13.9K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
206
Data Reporting and Recording01:24

Data Reporting and Recording

Reporting and recording are crucial in data documentation. The timely, thorough, and accurate documentation of facts is essential when recording patient data. Failure to record findings during an assessment or interpretation of a problem will result in loss of information and make the patient document unreliable. The reader is left with general impressions if the information is not specific. A recording is documenting data of the individual's health information in a traceable, secure, and...
5.5K
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
234
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.4K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
281
Hepatic Portal System01:21

Hepatic Portal System

The hepatic portal system, a critical part of our circulatory framework, transports nutrient-laden, deoxygenated blood from the gastrointestinal tract and spleen to the liver. This ingenious system plays an indispensable role in maintaining our body's metabolic equilibrium.
At its core, the hepatic portal vein is the result of a confluence of the superior and inferior mesenteric veins along with the splenic vein. Each of these veins has a unique role. The superior mesenteric vein is...
6.0K